IVERIC bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ISEE research report →
About the company
IVERIC bio, Inc. is a biopharmaceutical enterprise focused on identifying and advancing innovative therapeutic solutions for eye conditions, with a particular emphasis on age-related and rare inherited retinal diseases (IRDs). A cornerstone of its development pipeline is Zimura, an inhibitor targeting complement factor C5.
- CEO
- Glenn P. Sblendorio
- IPO
- 2013
- Employees
- 163
- HQ
- Parsippany, NJ, US
Price Chart
- Market Cap
- $5.51B
- P/E
- -27.55
- P/S
- 0.00
- P/B
- 9.04
- EV/EBITDA
- -28.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -39.26%
- ROIC
- -28.49%
- Revenue
- $0 · 0.00%
- Net Income
- $-175,745,000 · -53.84%
- EPS
- $-1.45 · -29.46%
- Op Income
- $-189,906,000
- FCF YoY
- -66.30%
- 52W High
- $39.99
- 52W Low
- $9.39
- 50D MA
- $38.02
- 200D MA
- $26.09
- Beta
- 1.10
- Avg Volume
- 4.95M
Get TickerSpark's AI analysis on ISEE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 11, 23 | Blumenkranz Mark S. | sell | 32,088 |
| Jul 11, 23 | Blumenkranz Mark S. | sell | 7,500 |
| Jul 11, 23 | Blumenkranz Mark S. | sell | 15,500 |
| Jul 11, 23 | Blumenkranz Mark S. | sell | 23,186 |
| Jul 11, 23 | Blumenkranz Mark S. | sell | 31,000 |
| Jul 11, 23 | Carroll David Francis | sell | 70,000 |
| Jul 11, 23 | Carroll David Francis | sell | 38,000 |
| Jul 11, 23 | Carroll David Francis | sell | 115,000 |
| Jul 11, 23 | Carroll David Francis | sell | 150,000 |
| Jul 11, 23 | Carroll David Francis | sell | 75,000 |
Our ISEE coverage
Recent articles, reports, and earnings notes.
No research on ISEE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ISEE report →Similar companies
Peers in the same neighborhood.